ArticleHepatology communications2026
Enhanced liver fibrosis score is associated with cognitive performance during an 11-year follow-up period.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic dysfunction-associated steatotic liver disease (MASLD) has been associated with poorer cognitive performance and greater cognitive decline. However, the liver-brain axis and the role of liver health in cognitive decline are still poorly understood. Thus, using both cross-sectional and longitudinal designs, we aimed to study how liver fibrosis score (ELF), an indicator of liver fibrosis, is associated with cognitive performance.
methodsThis study was based on the Health 2000 Survey and its follow-up, the Health 2011 survey, which collected data from a nationally representative sample of the Finnish adult population. At baseline, verbal fluency, wordlist learning, delayed wordlist recall, and simple and multiple-choice reaction time tests were conducted. At follow-up, all tests except the reaction time tests were repeated. A global z-score was derived from the individual cognitive domains. Multivariable regression analysis was performed to study the association between ELF and cognitive performance while adjusting for demographic, metabolic, and cardiovascular covariates.
resultsCross-sectionally (n=5115; mean age 53.2 y; 58.6% women), high ELF was associated with poorer global cognition and slower simple and multiple-choice reaction times compared with low ELF. High ELF was also associated with worse global cognition and performance in the wordlist learning test, both cross-sectionally and longitudinally (n=2490; mean age 48.7 y at baseline; 58.0% women). DISCUSSION: High ELF, an indicator of liver fibrosis, was associated with poorer global cognition both cross-sectionally and longitudinally. Worse performance was observed in cognitive domains that reflect poorer processing speed and executive function, verbal learning, attention, and working memory. These results imply that liver fibrosis could represent an early modifiable marker of cognitive vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.